Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor receptor-directed and MET receptor-directed antibody. From Wikipedia
Early results point to a more convenient frontline option with durability still unproven.
